Tumor response predicts survival time of ramucirumab plus irinotecan in advanced gastric cancer: An exploratory analysis of the phase III RINDBeRG trial

Category Primary study
ConferenceEuropean Society For Medical Oncology Congress, ESMO 2025
Year 2025
This article has no abstract
Epistemonikos ID: 5c441b35ca45635305fc1b143e5533adb235ad7d
First added on: May 16, 2026